SecBot SecBot
6-K ·Filed May 22, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago SEC0001776985-26-000037
Notable filing: 6-K
Actionable Insight • Neutral

Monitor ASCO presentations (May 30–June 1) for specific response rate, PFS, and OS data from the pumitamig and gotistobart abstracts, the interim data described is encouraging but lacks quantitative endpoints. The Phase 3 part of ROSETTA Lung-02 (pumitamig vs pembrolizumab) is the key catalyst to watch.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.14
T+0 close · May 22, 2026 · via day close
Latest settled
+0.66%
T+60 · $92.75
Vs SPY
−2.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $92.14entry
  2. T+1 · 6mo ago +0.12%α −0.47% · $92.25
  3. T+5 · 6mo ago −0.48%α −2.15% · $91.70
  4. T+20 · 5mo ago −1.03%α +0.39% · $91.19
  5. T+60 · 3mo ago +0.66%α −2.53% · $92.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, including new clinical data for pumitamig (Phase 2 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer), plus four trial-in-progress posters across its ADC and immunotherapy pipeline. The filing is a routine pipeline update with no new financial data, guidance, or regulatory milestones, the clinical data disclosed is interim and descriptive, not definitive.

Key Facts

  • BioNTech will present at ASCO 2026 (May 29–June 2) with two oral presentations and four poster presentations
  • Pumitamig (PD-L1/VEGF-A bispecific) Phase 2 data in 1L NSCLC shows 'encouraging anti-tumor activity', third global dataset with consistent signal
  • Gotistobart (CTLA-4) Phase 2 data in platinum-resistant ovarian cancer shows 'durable anti-tumor activity and clinically meaningful overall survival'
  • Company has 25+ Phase 2/3 trials including 13 ongoing pivotal trials and novel-novel combination trials including ADCs
  • No financial figures, guidance, or regulatory submission timelines were disclosed in the filing

Financial Impact

No financial data provided; pipeline update only

Risk Factors

  • Interim Phase 2 data may not replicate in larger Phase 3 trials
  • No regulatory filing or approval timeline provided, pipeline remains early-stage for these assets
  • Competitive landscape in 1L NSCLC (pembrolizumab standard of care) and platinum-resistant ovarian cancer (limited approved options) creates high bar for differentiation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000037
Document: form6-kascocurtainraiser22.htm0001776985-26-000037
Document: 0001776985-26-000037-index-headers.html0001776985-26-000037
Document: 0001776985-26-000037-index.html0001776985-26-000037
Document: 0001776985-26-000037.txt0001776985-26-000037

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026